First-in-human phase Ia study of the covalent TEAD palmitoylation inhibitor BPI-460372 in patients with advanced solid tumors: pharmacokinetics, exposure-limited dosing, and early antitumor activity.
BACKGROUND: The Hippo pathway is a critical regulator of tumor development and progression, dysregulation of the Hippo pathway drives tumorigenesis in multiple malignancies. CONCLUSION: BPI-460,372 demonstrated a distinct pharmacokinetic profile and showed preliminary antitumor activity in patients with advanced solid tumors.
BACKGROUND: The Hippo pathway is a critical regulator of tumor development and progression, dysregulation of the Hippo pathway drives tumorigenesis in multiple malignancies. CONCLUSION: BPI-460,372 demonstrated a distinct pharmacokinetic profile and showed preliminary antitumor activity in patients with advanced solid tumors.
What the study was
- Study design
- Journal Article
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Biomarker research
Why it surfaced
Score 7/10: Journal Article, human study, Exploratory. 🟠 NOVEL_TREATMENT — Novel or significantly improved treatment
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.